Indianapolis: Neuroimaging Opens Window to Disease, Better Diagnosis
Frontotemporal dementias pose a challenge for diagnosis because numerous overlapping clinical syndromes are associated with the disease...
ALL NEWS
472 RESULTS
Sort By:
- Most Recent
- Most Commented
An Oligomer Test for PD—Could One for AD Be Close Behind?
Small, soluble oligomers of amyloid-β (Aβ) are now widely believed to be the most toxic form of the peptide...
PPMI: Brain Imaging To Reveal Preclinical Parkinson’s Signature?
PPMI was launched in July with hopes of identifying a biomarker, or set of markers, that tracks the natural course of Parkinson disease...
PPMI: Parkinson's Field’s Answer to ADNI
One of the great challenges with developing treatments for neurodegenerative disorders stems from the capricious nature of disease progression...
Common Ground: Is Aβ the Foundation for Multiple Dementias?
The majority of patients with Parkinson disease eventually develop dementia, but what pathology underlies this decline?...
Triple Confirmation: AD Footprint in CSF of Cognitively Normal People
In clinical research, a first-time finding may rouse intrigue, but it’s generally independent confirmations of the data that give them potential to leave an indelible mark...
Honolulu: Biomarker Profiles That Spell Trouble for ‘Normals’?
Scientists have drafted a new set of diagnostic research criteria redefining AD as a condition that develops decades prior to obvious symptoms...
Revised Criteria for Preclinical AD, Exactly as Presented
Three workgroups of clinicians from the U.S. and Europe offered new guidelines for the diagnosis of AD...
Noisy Response Greets Revised Diagnostic Criteria for AD
Three groups presented results of their ongoing effort to incorporate scientific advances of the past quarter-century into a revision of the current diagnostic AD criteria...
DIAN Dispatch from Hawaii: Glimpse at Data, Push for Trials
Leaders of DIAN gathered to brief each other to present to some 30 pharmaceutical industry scientists the first cut of baseline data from this ongoing biomarker study...
New Findings Offer Hope for Down Syndrome
Conventional wisdom says that Down syndrome (DS) goes hand-in-hand with intellectual disability—but what if that was not true?...
Miami Beach: Biomarkers Weigh In at MCI Meeting
The Alzforum brings you a journalistic summary by reporter Pat McCaffrey enhanced by slide decks from the majority of presentations...
Classifying Motor Neuron Disease With CSF Markers
It is easy to confuse one motor neuron disease for another: amyotrophic lateral sclerosis, primary lateral sclerosis, and lower motor neuron disease can all mimic each other...
Geneva: Biomarker News Morsels Amid Immunotherapy Review
Advances in therapy saw little sprigs of news pop up in talks that otherwise took stock of the current status of immunotherapy as one of the major new approaches...
CSF Biomarkers Track With Atrophy, Cognition in Normal Aging
When judging the utility of cerebrospinal fluid biomarkers in Alzheimer disease, it may be less a question of if, but rather when and in whom...